Our hollow-fiber infection model simulated the projected steady-state pharmacokinetics of ceftolozane and tazobactam in lung epithelial lining fluid of patients with pneumonia receiving 3 g of ceftolozane/tazobactam every 8 hours. Results confirmed the previously established in vitro activity of ceftolozane/tazobactam at and above approved breakpoints against multidrug-resistant Pseudomonas aeruginosa, regardless of Pseudomonas-derived cephalosporinase allele.
CITATION STYLE
Carr, D., Zhang, Z., Si, Q., Racine, F., Xiao, J. C., Katwaru, R., … Motyl, M. (2020). In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam against Multidrug-Resistant Pseudomonas Aeruginosa. Open Forum Infectious Diseases, 7(11). https://doi.org/10.1093/ofid/ofaa469
Mendeley helps you to discover research relevant for your work.